"Designing Growth Strategies is in our DNA"

U.S. Diabetes Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Others), By Diabetes Type (Type 1 and Type 2), By Route of Administration (Oral, Subcutaneous, and Intravenous), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies), and Country Forecast, 2023-2030

Last Updated: February 17, 2025 | Format: PDF | Report ID: FBI109115

 

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Diabetes, by Type, for Key Countries / Region, 2022
    2. Pipeline Analysis, by Key Players
    3. New Product Launches, by Key Players
    4. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
    5. Impact of COVID-19 on U.S. Diabetes Drugs Market
  5. U.S. Diabetes Drugs Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Insulin
      2. DPP-4 Inhibitors
      3. GLP-1 Receptor Agonists
      4. SGLT2 Inhibitors
      5. Others
    2. Market Analysis, Insights and Forecast – By Diabetes Type
      1. Type-1
      2. Type-2
    3. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Subcutaneous
      3. Intravenous
    4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospitals Pharmacies
      2. Retail Pharmacies & Stores
      3. Online Pharmacies
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2022)
    2. Company Profiles
      1. Sanofi
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      2. Merck & Co., Inc.
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      3. Novo Nordisk A/S
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      4. Lilly
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      5. AstraZeneca
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      6. Takeda Pharmaceutical Company Limited
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      7. Novartis AG
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      8. Boehringer Ingelheim International GmbH
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      9. Johnson & Johnson Services Inc.
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
      10. Bayer AG
        1. Overview
        2. Products
        3. SWOT analysis
        4. Recent developments
        5. strategies
        6. financials (based on availability)
Read Less

Figure 1: U.S. Diabetes Drugs Market Revenue Breakdown (USD billion, %) by Drug Class, 2022 & 2030

Figure 2: U.S. Diabetes Drugs Market Value Share (%), by Drug Class, 2022 & 2030

Figure 3: U.S. Diabetes Drugs Market Value Share (%), by Diabetes Type, 2022 & 2030

Figure 4: U.S. Diabetes Drugs Market Value Share (%), by Route of Administration, 2022 & 2030

Figure 5: U.S. Diabetes Drugs Market Value Share (%), by Distribution Channel, 2022 & 2030

Figure 6: U.S. Diabetes Drugs Market Share (%), By Company, 2022

Table 1: U.S. Diabetes Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2019–2030

Table 2: U.S. Diabetes Drugs Market Revenue (USD billion) Forecast, by Diabetes Type, 2019–2030

Table 3: U.S. Diabetes Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2030

Table 4: U.S. Diabetes Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2030

U.S. Diabetes Drugs Market Size, Share and Global Industry Trend Forecast till 2030
  • 2019-2030
  • 2022
  • 2019-2021
  • 80
Consulting Services
    How will you benefit from our consulting services ?